GlassScriptPhysician profile
William A Gammill
NPI 1437199908
$13,397.45
in general payments reported to CMS, 2019-2025
51 companies · $1,545 in 2025
The $1,545 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,363 · 2020: $2,073 · 2021: $2,108 · 2022: $1,947 · 2023: $1,807 · 2024: $1,554 · 2025: $1,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,905.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,373.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,237.58 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,197.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $1,092.79 | 2019-2022 | |
| Lilly USA, LLC | $1,001.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $922.91 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $919.94 | 2019-2025 | |
| Amgen INC. | $736.24 | 2019-2025 | Repatha, Evenity, Repatha |
| Allergan, INC. | $518.24 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.87 | 2019-2024 | Jardiance, Tradjenta, Stiolto Respimat |
| Corcept Therapeutics | $385.37 | 2020-2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $338.23 | 2019-2023 | |
| Axsome Therapeutics, INC. | $316.66 | 2023-2025 | Auvelity, Symbravo |
| Merck Sharp & Dohme LLC | $315.22 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $285.15 | 2021-2025 | Rexulti |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gammill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.